key: cord-0855067-xtaocdue
authors: Wey, Emmanuel Q.; Bristow, Clare; Nandani, Aarti; O'Farrell, Bryan; Pang, Jay; Lanzman, Marisa; Yang, Shuang; Ho, Soo; Mack, Damien; Spiro, Michael; Balakrishnan, Indran; Bhagani, Sanjay; Pollara, Gabriele
title: Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
date: 2021-08-14
journal: J Infect
DOI: 10.1016/j.jinf.2021.08.017
sha: 0f78b689fd3e8866e36ac2b131c4e949879f4a25
doc_id: 855067
cord_uid: xtaocdue

nan

In inflammatory arthritides, multiple tocilizumab dosing variably attenuates CRP responses following bacterial infections 6 , but the effect following single-dose use in COVID-19 is not defined 2, 7 . In a small COVID-19 cohort with blood stream infections (BSIs) that had received tocilizumab, CRP was reduced but remained detectable at the time of BSI diagnosis 8 . However, CRP kinetics related to BSI were not assessed, and thus the utility of CRP to guide antibiotic prescribing in this context remains unknown 5, 9 . We addressed this question by testing the hypothesis that a single dose of tocilizumab for COVID-19 retained CRP responses to bacterial infections, as modelled by BSIs.

We identified patients admitted to Royal Free Hospital (RFH) between 01/03/2020 and 01/02/2021, aged >18 years and diagnosed with COVID-19 by RT-PCR detection of SARS-CoV-2 from nasopharyngeal swabs. Tocilizumab use originated from routine clinical care delivery or randomised clinical trials after unblinding. COVID-19 associated BSIs were defined by isolation in blood cultures of any bacteria, excluding coagulase negative staphylococci, between 14 days prior to and 60 days after COVID-19 diagnosis. We excluded patients that developed BSIs prior to receiving tocilizumab. To assess dynamic CRP responses, we included only patients with blood parameter measurements performed at least 3 days prior to the onset of BSIs. Clinical, laboratory and drug data extraction, and statistical analyses were performed as previously described 5 . The study was approved by the Research and Innovation Group at RFH, which stated that as this was a retrospective review of routine clinical data, formal ethics approval was not required.

Within the COVID-19 patients that met our inclusion criteria, 107 had received tocilizumab, 17 of whom then developed a BSI during their hospital admission (table 1). A separate cohort of 55 COVID-19 patients developed a BSI but had not received tocilizumab (table 1) . Tocilizumab use preceding BSIs was more commonly associated with ICU admission, but the BSI organisms were comparable between the groups (table 1). In the first week after tocilizumab administration we observed a rapid fall in CRP ( fig 1A) , but not for total white cell, neutrophil or lymphocyte counts ( fig 1A & fig S1) . The CRP reduction following tocilizumab was short lived, with CRP concentrations rising within 21 days of tocilizumab receipt ( fig 1A) . To exclude confounding by bacterial co-infection, a sensitivity analysis on 90 patients that did not develop a BSI following tocilizumab also showed an early reduction followed by a rebound in CRP ( fig S2A) . A similar pattern was evident in patients that developed a BSI, although CRP concentrations showed less attenuation and greater heterogeneity within the 21-day period since tocilizumab administration ( fig S2B) .

To test the hypothesis that CRP would rise following a BSI independent of prior tocilizumab administration, we compared CRP responses in 17 patients that had received tocilizumab prior to a BSI with 55 patients who had not received tocilizumab. Strikingly, in both cohorts, BSIs resulted in clear CRP elevations (figs 1B & 1C). We calculated the change in CRP across the time of BSI onset to quantitatively compare this CRP rise. As blood samples were not collected daily in all patients, we derived paired sampling by calculating maximal CRP values 2 or 3 days prior to BSI-detecting blood culture collection and maximal CRP up to 2 days after BSI. This approach revealed an increase in CRP following BSI in 76.5% and 75.0% of patients that had or had not received tocilizumab respectively ( fig 1D) . Moreover, there was no difference in CRP increase between the groups (median CRP change +88 mg/L vs +76 mg/L respectively, p = 0.67 by Mann-Whitney test).

As patients developed BSIs at varying times following receipt of tocilizumab, we tested the hypothesis that BSI-induced CRP increment would be proportional to the time interval between tocilizumab administration and BSI onset. However, in the 17 patients that both received tocilizumab and subsequently developed a BSI, no relationship was observed between the length of the tocilizumab-BSI interval and the change in CRP (r = 0.1069, p=0.6811 by Rank-spearman correlation) ( fig 1E) .

By inhibiting IL-6 signalling, tocilizumab may impact CRP-guided antibiotic prescribing decisions 5, 9 . However, we demonstrate that prior administration of a single dose of tocilizumab does not attenuate CRP responses following a BSI, retaining the utility of this biomarker to diagnose bacterial co-infections associated with COVID-19. These findings have important implications for tocilizumab-treated COVID-19 patients: first, clinically-indicated antibiotic prescriptions are unlikely to be delayed, and second, low CRP levels alone are not an indication for continued prescription of unnecessary antibiotics, supporting stewardship efforts. Nevertheless, BSI onset did not initiate CRP elevations in all patients, irrespective of prior tocilizumab use, emphasising that CRP is only one contributor to diagnosing incipient bacterial infections.

Despite preserved CRP responses to BSI, tocilizumab transiently reduced baseline CRP levels, mostly recovering within 21 days. Furthermore, BSI-associated CRP increments were unrelated to time since tocilizumab, indicating that single tocilizumab dosing may not completely neutralise IL-6 responses 10 , although a role for IL-6-independent CRP stimuli cannot be excluded. Measuring IL-6 signalling activity in vivo may predict attenuation of CRP responses and inform the need for further tocilizumab dosing in COVID-19 7 .

Our study was limited by its single-centre and retrospective nature, constraining patient numbers and negating correction for potential confounders. Nevertheless, increased frequency of corticosteroid use in tocilizumab recipients could have further attenuated CRP responses, counter to our observations. BSIs provided a standardised definition for bacterial infections, but limited extrapolation to non-BSI settings, an area of required future work to confirm the generalisability of our findings.

In conclusion, we show that tocilizumab use in severe COVID-19 preserves elevations in CRP concentration following the onset of a confirmed bacterial co-infection, as modelled by BSIs. Use of tocilizumab should not negate judicious, CRP-guided use of antibiotics in COVID-19.

We declare that all authors have no conflicts of interest 

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe

Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics

Risk of infections in rheumatoid arthritis patients treated with tocilizumab

Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19. iScience

Bloodstream infections in critically ill patients with COVID-19

Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses